{
  "id": 914272,
  "title": "Earnings call transcript: PetVivo lifts revenue in Q1 2026, but stock stays flat",
  "url": "https://urgent.news/2026/08/14/earnings-call-transcript-petvivo-lifts-revenue-in-q1-2026-but-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-14T22:31:02.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-petvivo-lifts-revenue-in-q1-2026-but-stock-stays-flat-93CH-4861613"
  },
  "original_language": "en",
  "account": "PetVivo reported a 13% increase in first-quarter revenue to $338,000, while its net loss narrowed to $0.05 per share. The veterinary medical device company credits its higher-margin SPRYNG product and cost reductions for the improvement. Distributor revenue made up about 82% of total sales. The company has shifted focus to the proprietary SPRYNG product, which helped lift margins and reduce dependence on outside products. Operating loss narrowed 13% to $1.6 million, and total operating expenses fell 10% to $1.8 million. Despite the gains, PetVivo remains pre-profitable, trading at $0.97, about unchanged and well below its 52-week high. Analysts view the company as overvalued and in a pre-profitability stage with limited cash reserves. Management expects continued revenue growth and improved margins as they expand sales teams, enter Canada, and develop new products.",
  "summary": null,
  "key_points": [
    "PetVivo reports 13% revenue increase to $338,000 in Q1 2026",
    "Net loss narrows to $0.05 per share, operating loss down 13%",
    "Stock price remains flat at $0.97 despite positive earnings"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}